雷贝拉唑联合莫沙必利治疗功能性消化不良41例

Curative Effect of Rabeprazole Combined with Mosapride on 41 Patients with Functional Dyspepsia

目的:观察雷贝拉唑联合莫沙必利治疗功能性消化不良(FD)的疗效。方法:80例FD患者随机分为观察组41例和对照组39例。两组患者均予莫沙必利胶囊5mg,po tid(餐前30min服用),连续服用8周。观察组在此础上加用雷贝拉唑钠肠溶胶囊10 mg,po qd,连续服用8周。随访观察6个月,比较两组临床疗效和不良反应。结果:治疗8周后,观察组疗效显著高于对照组(P<0.05)。观察组出现不良反应2例,对照组出现不良反应4例,症状均较轻,不影响治疗。随访观察6个月,观察组复发率明显低于对照组(P<0.05)。结论:雷贝拉唑联合莫沙必利治疗FD,能持续缓解患者的临床症状,安全性好,复发率低。

Objective：To observe the curative effect of rabeprazole combined with mosapride on 40 patients with functional dyspepsia（FD）. Methods： 80 patients with FD were randomly divided into the observation group and controlled group. All the patients took mosapride capsule 5mg orally, 3 times a day, half an hour before meal for 8 weeks. The patients of the observation group got extra treatment by taking rabeprazole sodium enteric-coated capsules 10mg orally once a day for 8 weeks. The clinic curative effect and adverse reaction were observed for 6 month. Results：8 weeks after treatment, the curative effect of the observation group was better than that of the controlled group（ P〈0.05）. 2 cases of adverse reaction were found in the controlled group, 1 was bellyache and the other was diarrhea; 4 cases were found in the observation group, 1 was rash and the other 3 were diarrhea. All of these symptoms were mild and did not influence treatment. The responders of the two groups were followed for 6 months. The recurrence rate of the observation group was significantly lower than that of the controlled group （P〈0.05）. Conclusion： Treating FD with rabeprazole combined with mosapride was safe and could relieve the symptom of the patient and reduce the recurrence rate.